SomaLogic acquires DNA nanotechnology leader Palamedrix to develop the next-generation SomaScan® Assay

SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced it entered into an agreement to acquire Palamedrix, Inc., an innovator in DNA nanotechnology. Palamedrix pro...

Learn More

Cerebral Therapeutics, Inc. Secures $40 Million Series C Financing

Cerebral Therapeutics, a clinical-stage pharmaceutical company pioneering therapies for neurological diseases, announced today $40 million in Series C funding led by Lynx1 Capital Management with part...

Learn More

Weekly Policy Update: Senate Prescription Drug Pricing Legislation

Democrats in the U.S. Senate continue to negotiate an economic package that advances President Joe Biden’s key priorities. Prescription drug pricing legislation that would drastically alter the Medica...

Learn More

Securisyn Medical Announces Strategic Manufacturing and Distribution Partnership with SunMed Group Holdings

Securisyn Medical LLC, (“Securisyn” or the “Company”), an emerging medical device company dedicated to enhancing ventilated patient safety and broader smooth tube and catheter securement, and SunMed G...

Learn More

Philips Incorporates Biodesix Blood-based Proteomic Nodule Risk Assessment Testing into Lung Cancer Orchestrator to Advance Early Lung Cancer Diagnosis

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has teamed up with Biodesix, Inc. (Colorado, U.S.) (Nasdaq: BDSX), a leading data-dri...

Learn More

Morgridge Family Foundation gifts $3M to CSU Spur and College of Agricultural Sciences

The Morgridge Family Foundation has imparted a transformational gift of $3 million to support the Colorado State University College of Agricultural Sciences and educational program...

Learn More

Biodesix Announces Research Agreement with Top US Cancer Center

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that it intends to develop a new novel minimal residual disease (MRD) te...

Learn More

Watchmaker Genomics Raises $40M Series A Financing to Accelerate Growth and Expand Clinical Sequencing Product Offerings

Watchmaker Genomics, a life sciences company specializing in the development of high-stringency applications focused on the reading, writing, and editing of DNA and RNA, today announced it had secured...

Learn More

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription...

Learn More

AGC Biologics Invests in Viral Vector Suspension at New U.S. Campus

AGC Biologics today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA...

Learn More